These combinations include: cetuximab, in advanced lung cancer (NCT00368992); MEDI3617 (anti-Ang-2) (238), for advanced solid malignancies (NCT01248949); the mAb drozitumab (PRO95780) (223) against death receptor 5 (DR5/TRAIL-R2), in metastatic colorectal cancer (NCT00851136); NK immunotherapy, in recurrent solid tumors (NCT02857920); and atezolizumab (NCT03038100, NCT02659384), nivolumab (NCT02873962), or pembrolizumab (NCT02853318) for the treatment of ovarian, fallopian tube, or primary peritoneal cancer. Here, TNFRSF10B is linked to metastatic colorectal cancer.